We also looked at the impact of the HTCT on HERV-V2 mRNA and protein levels by treating OvCar3 cells with lower drug doses compared to SKOV3WT and subjecting the remaining tumour mass to qPCR and IHC: HERV-V2 mRNA and protein levels mirrored the observed in vitro effects after romidepsin-vesatolimod combination treatment (Fig. 8c), while vesatolimod alone had a distinct reducing effect (Fig. 8d). Here, ERVV-2 is linked to neoplasm.